基于微生物-肠-脑轴理论探讨迷走神经刺激治疗帕金森病的研究进展*

doi:10.3870/j.issn.1672-0741.25.08.026

摘要/Abstract

摘要： 帕金森病的发病机制较为复杂,目前尚无完全治愈的方法。近年来随着对微生物-肠-脑轴的深入研究,发现肠道微生物与大脑之间的双向通讯可通过迷走神经介导,且微生物-肠-脑轴与帕金森病关系密切,是帕金森病的诊疗方向之一。该文旨在构建以“肠道菌群失调-迷走神经介导-α-突触核蛋白-帕金森病”为核心的框架,梳理以迷走神经为靶点的干预策略,通过分析其调节肠道菌群及神经保护等的多重机制,进一步阐明其在改善帕金森病运动与非运动症状方面的独特优势,进一步探讨迷走神经刺激治疗帕金森病的潜力。

关键词: 微生物-肠-脑轴, 肠道微生物, 迷走神经, 迷走神经刺激, 帕金森病

Abstract: The pathogenesis of Parkinson’s disease is rather complex,and no complete cure is currently available.Recent in-depth studies on the microbiota-gut-brain axis have revealed that bidirectional communication between gut microbiota and the brain is mediated by the vagus nerve.The microbiota-gut-brain axis is closely associated with Parkinson’s disease and represents a promising direction for its diagnosis and treatment.This paper aims to construct a framework centered on“gut microbiota dysbiosis-vagus nerve mediation-α-synuclein-Parkinson’s disease”,organizing intervention strategies targeting the vagus nerve.By analyzing its multiple mechanisms,such as regulating gut microbiota and providing neuroprotection,the study further elucidates its unique advantages in improving both motor and non-motor symptoms of Parkinson’s disease,thereby exploring the potential of vagus nerve stimulation as a treatment for the condition.

Key words: microbiota-gut-brain axis, microbiota, vagus nerve, vagus nerve stimulation, Parkinson’s disease

中图分类号:

R742.5

吴新, 任彬彬. 基于微生物-肠-脑轴理论探讨迷走神经刺激治疗帕金森病的研究进展^*[J]. 华中科技大学学报（医学版）, 2026, 55(3): 443-449.

Wu Xin, Ren Binbin. Research Progress on Vagus Nerve Stimulation for Parkinson’s Disease Based on the Microbiota-Gut-Brain Axis Theory[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(3): 443-449.

参考文献

[1] Armstrong M J,Okun M S.Diagnosis and treatment of Parkinson disease:A review[J].JAMA,2020,323(6):548-560.
[2] Dorsey E R,Sherer T,Okun M S,et al.The emerging evidence of the Parkinson pandemic[J].J Park Dis,2018,8(s1):S3-S8.
[3] 张森,赵晓悦,梁宇,等.帕金森病致病因素及发病机制研究进展[J].药学学报,2020,55(10):2264-2272.
Zhang S,Zhao X Y,Liang Y,et al.Advances in understanding the pathogenic factors and pathogenesis of Parkinson’s disease[J].Acta Pharmaceutica Sinica,2020,55(10):2264-2272.
[4] Braak H,Rüb U,Gai W P,et al.Idiopathic Parkinson’s disease:Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen[J].J Neural Transm,2003,110(5):517-536.
[5] Shannon K M,Keshavarzian A,Dodiya H B,et al.Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s Disease? Evidence from 3 cases[J].Mov Disord,2012,27(6):716-719.
[6] Holmqvist S,Chutna O,Bousset L,et al.Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats[J].Acta Neuropathol,2014,128(6):805-820.
[7] Cryan J F,O’Riordan K J,Cowan C S M,et al.The microbiota-gut-brain axis.[J].Physiol Rev,2019,99(4):1877-2013.
[8] Wahlström A,Sayin S I,Marschall H U,et al.Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J].Cell Metab,2016,24(1):41-50.
[9] Luxenburger A,Clemmens H,Hastings C,et al.3α,7-dihydroxy-14(13→12)abeo-5β,12α(H),13β(H)-cholan-24-oic acids display neuroprotective properties in common forms of Parkinson’s disease[J].Biomolecules,2022,13(1):76.
[10] Heinken A,Ravcheev D A,Baldini F,et al.Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease[J].Microbiome,2019,7(1):75.
[11] Li P,Killinger B A,Ensink E,et al.Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson’s disease[J].Metabolites,2021,11(1):29.
[12] Cuevas E,Burks S,Raymick J,et al.Tauroursodeoxycholic acid(TUDCA)is neuroprotective in a chronic mouse model of Parkinson’s disease[J].Nutr Neurosci,2022,25(7):1374-1391.
[13] Hatano T,Oyama G,Shimo Y,et al.Efficacy and safety of elobixibat in Parkinson’s disease with chronic constipation:CONST-PD study[J].Mov Disord Clin Pract,2024,11(4):352-362.
[14] Magliocca G,Mone P,Di Iorio B R,et al.Short-chain fatty acids in chronic kidney disease:Focus on inflammation and oxidative stress regulation[J].Int J Mol Sci,2022,23(10):5354.
[15] denBesten G,van Eunen K,Groen A K,et al.The role of short-chain fatty acids in the interplay between diet,gut microbiota,and host energy metabolism[J].J Lipid Res,2013,54(9):2325-2340.
[16] Silva Y P,Bernardi A,Frozza R L.The role of short-chain fatty acids from gut microbiota in gut-brain communication[J].Front Endocrinol,2020,11:25.
[17] Erny D,Hrabě de Angelis A L,Jaitin D,et al.Host microbiota constantly control maturation and function of microglia in the CNS[J].Nat Neurosci,2015,18(7):965-977.
[18] Salim S,Ahmad F,Banu A,et al.Gut microbiome and Parkinson’s disease:perspective on pathogenesis and treatment[J].J Adv Res,2023,50:83-105.
[19] Sampson T R,Debelius J W,Thron T,et al.Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease[J].Cell,2016,167(6):1469-1480.e12.
[20] Wu G,Jiang Z,Pu Y,et al.Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients[J].BMC Neurol,2022,22(1):13.
[21] Chen S J,Chen C C,Liao H Y,et al.Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease[J].Neurology,2022,98(8):848-858.
[22] Cai B,Zhong L,Wang Q,et al.Curcumin alleviates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease in mice via modulating gut microbiota and short-chain fatty acids[J].Front Pharmacol,2023,14:1198335.
[23] Roth W,Zadeh K,Vekariya R,et al.Tryptophan metabolism and gut-brain homeostasis[J].Int J Mol Sci,2021,22(6):2973.
[24] Tanaka M,Toldi J,Vécsei L.Exploring the etiological links behind neurodegenerative diseases:inflammatory cytokines and bioactive kynurenines[J].Int J Mol Sci,2020,21(7):2431.
[25] Savitz J.The kynurenine pathway:a finger in every pie[J].Mol Psychiatry,2020,25(1):131-147.
[26] Wilson E,Umans J,Swarovski M,et al.Parkinson’s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction[J].NPJ Parkinsons Dis,2025,11(1):96.
[27] Ogawa T,Matson W R,Beal M F,et al.Kynurenine pathway abnormalities in Parkinson’s disease[J].Neurology,1992,42(9):1702-1706.
[28] Wang Y,Chen S,Tan J,et al.Tryptophan in the diet ameliorates motor deficits in a rotenone-induced rat Parkinson’s disease model via activating the aromatic hydrocarbon receptor pathway[J].Brain Behav,2021,11(8):e2226.
[29] Wang J Y,Chen J Y,Lian Y Z,et al.Reduced platelet 5-HT content is associated with rest tremor in Parkinson’s disease[J].Parkinsonism Relat Disord,2023,108:105314.
[30] Richard I H,McDermott M P,Kurlan R,et al.A randomized,double-blind,placebo-controlled trial of antidepressants in Parkinson disease[J].Neurology,2012,78(16):1229-1236.
[31] Mertsalmi T H,Pekkonen E,Scheperjans F.Antibiotic exposure and risk of Parkinson’s disease in Finland:a nationwide case-control study[J].Mov Disord,2020,35(3):431-442.
[32] Ternák G,Németh M,Rozanovic M,et al.Antibiotic consumption patterns in European countries are associated with the prevalence of Parkinson’s disease;the possible augmenting role of the narrow-spectrum penicillin[J].Antibiotics,2022,11(9):1145.
[33] Zhou X,Lu J,Wei K,et al.Neuroprotective effect of ceftriaxone on MPTP-induced Parkinson’s disease mouse model by regulating inflammation and intestinal microbiota[J].Oxid Med Cell Longev,2021,2021(1):9424582.
[34] Dominguez-Meijide A,Parrales V,Vasili E,et al.Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo[J].Neurobiol Dis,2021,151:105256.
[35] Sudo N.Microbiome,HPA axis and production of endocrine hormones in the gut[J].Adv Exp Med Biol,2014,817:177-194.
[36] Magistrelli L,Amoruso A,Mogna L,et al.Probiotics may have beneficial effects in Parkinson’s disease:in vitro evidence[J].Front Immunol,2019,10:969.
[37] Tan A H,Lim S Y,Chong K K,et al.Probiotics for constipation in Parkinson disease:A randomized placebo-controlled study[J].Neurology,2021,96(5):772-782.
[38] Chu C,Yu L,Li Y,et al.Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson’s disease[J].Food Funct,2023,14(8):3406-3422.
[39] Brandt L J,Aroniadis O C.An overview of fecal microbiota transplantation:techniques,indications,and outcomes[J].Gastrointest Endosc,2013,78(2):240-249.
[40] Zhao Z,Ning J,Bao X Q,et al.Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis[J].Microbiome,2021,9(1):226.
[41] Kuai X Y,Yao X H,Xu L J,et al.Evaluation of fecal microbiota transplantation in Parkinson’s disease patients with constipation[J].Microb Cell Fact,2021,20(1):98.
[42] Cheng Y,Tan G,Zhu Q,et al.Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease:Clinical trial results from a randomized,placebo-controlled design[J].Gut Microbes,2023,15(2):2284247.
[43] Segal A,Zlotnik Y,Moyal-Atias K,et al.Fecal microbiota transplant as a potential treatment for Parkinson’s disease-A case series[J].Clin Neurol Neurosurg,2021,207:106791.
[44] Raybould H E.Gut chemosensing:interactions between gut endocrine cells and visceral afferents[J].Auton Neurosci,2010,153(1/2):41-46.
[45] Chandra R,Hiniker A,Kuo Y M,et al.α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease[J].JCI Insight,2017,2(12):e92295.
[46] Chapelet G,Béguin N,Castellano B,et al.Tau expression and phosphorylation in enteroendocrine cells[J].Front Neurosci,2023,17:1166848.
[47] Johnston G R,Webster N R.Cytokines and the immunomodulatory function of the vagus nerve[J].Br J Anaesth,2009,102(4):453-462.
[48] Ben-Menachem E.Vagus nerve stimulation,side effects,and long-term safety[J].J Clin Neurophysiol,2001,18(5):415-418.
[49] Abbott N J.Inflammatory mediators and modulation of blood-brain barrier permeability[J].Cell Mol Neurobiol,2000,20(2):131-147.
[50] Glass C K,Saijo K,Winner B,et al.Mechanisms underlying inflammation in neurodegeneration[J].Cell,2010,140(6):918-934.
[51] Farrand A Q,Helke K L,Gregory R A,et al.Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson’s disease[J].Brain Stimul,2017,10(6):1045-1054.
[52] Hosomoto K,Sasaki T,Yasuhara T,et al.Continuous vagus nerve stimulation exerts beneficial effects on rats with experimentally induced Parkinson’s disease:Evidence suggesting involvement of a vagal afferent pathway[J].Brain Stimul,2023,16(2):594-603.
[53] Lench D H,Turner T H,McLeod C,et al.Multi-session transcutaneous auricular vagus nerve stimulation for Parkinson’s disease:evaluating feasibility,safety,and preliminary efficacy[J].Front Neurol,2023,14:1210103.
[54] Han W,Tellez L A,Perkins M H,et al.A neural circuit for gut-induced reward[J].Cell,2018,175(3):665-678.e23.
[55] Wang C,Su T,Xiao L,et al.Right vagus nerve stimulation improves motor behavior by exerting neuroprotective effects in Parkinson’s disease rats[J].Ann Transl Med,2022,10(24):1314.
[56] Pifl C,Rajput A,Reither H,et al.Is Parkinson’s disease a vesicular dopamine storage disorder? evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum[J].J Neurosci,2014,34(24):8210-8218.
[57] van Midden V,Simončič U,Pirtošek Z,et al.The effect of taVNS at 25 Hz and 100 Hz on Parkinson’s disease gait-a randomized motion sensor study[J].Mov Disord,2024,39(8):1375-1385.
[58] Kaut O,Janocha L,Weismüller T J,et al.Transcutaneous vagal nerve stimulation improves gastroenteric complaints in Parkinson’s disease patients[J].NeuroRehabilitation,2019,45(4):449-451.
[59] Zhang H,Cao X Y,Wang L N,et al.Transcutaneous auricular vagus nerve stimulation improves gait and cortical activity in Parkinson’s disease:a pilot randomized study[J].CNS Neurosci Ther,2023,29(12):3889-3900.
[60] Menekseoglu A K.Acute effect of transcutaneous auricular vagus nerve stimulation on hand tremor in Parkinson’s disease:a pilot study of case series[J].Sisli Etfal Hastan Tip Bul,2023,57(4):513-519.
[61] Zhang H,Shan A D,Huang Y Y,et al.Transcutaneous auricular vagus nerve stimulation improves cortical functional topological properties and intracortical facilitation in patients with Parkinson’s disease[J].NPJ Parkinsons Dis,2025,11(1):38.
[62] Marano M,Anzini G,Saltarocchi L,et al.Left vagus stimulation modulates contralateral subthalamic β power improving the gait in Parkinson’s disease[J].Mov Disord,2024,39(2):424-428.
[63] Zhang H,Shan A D,Wan C H,et al.Transcutaneous auricular vagus nerve stimulation improves anxiety symptoms and cortical activity during verbal fluency task in Parkinson’s disease with anxiety[J].J Affect Disord,2024,361:556-563.

基于微生物-肠-脑轴理论探讨迷走神经刺激治疗帕金森病的研究进展^*

Research Progress on Vagus Nerve Stimulation for Parkinson’s Disease Based on the Microbiota-Gut-Brain Axis Theory

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	李筱婷, 王超群, 高义昆, 叶樱泽, 古丽娟. 质子泵抑制剂与缺血性脑卒中的因果关系及肠道微生物紊乱的中介效应^*[J]. 华中科技大学学报（医学版）, 2026, 55(3): 309-318.
[2]	赵自豪, 魏涛华, 杨文明, 钱南南, 宋宇琪, 王玮琦, 李杨阳, 徐福琳. 1990~2021年中国帕金森病疾病负担分析及2035年预测:与全球的对比分析^*[J]. 华中科技大学学报（医学版）, 2026, 55(3): 378-386.
[3]	李艳辉, 张汤安苏, 陈锦华, 余舒扬, 汪宏波. 直肠拭子与粪便取样两种途径采集的标本中肠道微生物群组成及功能对比分析[J]. 华中科技大学学报（医学版）, 2025, 54(5): 617-625.
[4]	阎瑾逸, 李志军. 肠道微生态与神经系统自身免疫性疾病[J]. 华中科技大学学报（医学版）, 2024, 53(4): 539-453.
[5]	杨小曼, 徐岩, 曹学兵. 神经退行性疾病中轴突运输障碍的机制[J]. 华中科技大学学报（医学版）, 2024, 53(4): 558-562.
[6]	王丹宁, 徐卉. 细胞外囊泡介导的肠-脑交互机制在中枢神经系统疾病中的研究进展[J]. 华中科技大学学报（医学版）, 2023, 52(3): 413-418.
[7]	马敬, 仲照希, 岳凌峰, 王瑜璞 , 李炎. 阿立哌唑改善帕金森病伴发抑郁模型大鼠行为学及能量代谢[J]. 华中科技大学学报（医学版）, 2023, 52(2): 200-205.
[8]	李艳辉, 赵蓉, 肖诚瑀, 汪宏波. 高脂饮食诱导的子宫内膜不典型增生小鼠肠道菌群微生物组学研究[J]. 华中科技大学学报（医学版）, 2022, 51(2): 139-145.
[9]	刘欣媛, 陶一鸣, 杜艳军, △ , 曾鹏, 田青, 李蔚娴. Shh信号参与神经退行性疾病神经元分化与再生的研究进展[J]. 华中科技大学学报（医学版）, 2022, 51(1): 134-138.